COMMUNIQUÉS West-GlobeNewswire

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09/12/2024 - 18:00

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Ipsen - Novembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

09/12/2024 - 18:00

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board

09/12/2024 - 17:00

Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors NEW YORK, Dec. 09, 2024 (GLOBE [...]

Novo Nordisk A/S - share repurchase programme

09/12/2024 - 16:43

Bagsværd, Denmark, 9 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]

Monica Lewinsky Visits Agnivesh Agarwal’s Primeks Medical in Istanbul

09/12/2024 - 16:43

ISTANBUL, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Social activist Monica Lewinsky visited Istanbul in October at the invitation of Agnivesh Agarwal, founder of Primeks Medical, a medical supplies company with investment [...]

COVID Vaccines’ Genetic Mechanism Inadequately Tested, according to Journal of American Physicians and Surgeons (AAPS)

09/12/2024 - 16:22

TUCSON, Ariz., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The regulatory framework has broken down for Pfizer/BioNTech’s COVID-19 vaccines, write Philip Oldfield and coauthors in the winter issue of the Journal of American [...]

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

09/12/2024 - 15:33

- Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s formal remarks, there will be a question-and-answer session [...]

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

09/12/2024 - 15:15

Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of [...]

Healthcare Integrated Technologies welcomes former Google Executive & Head of Sales Enablement, Theo Davies as Chief Commercial Officer

09/12/2024 - 15:15

Nashville, TN, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, proudly announces the appointment of Theo Davies as its [...]

UPDATE: MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units

09/12/2024 - 15:14

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, [...]

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

09/12/2024 - 15:00

Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc [...]

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

08/12/2024 - 20:12

Étude du pétosemtamab en association avec le pembrolizumab en 1re ligne de traitement dans le CETC r/m exprimant PD-L1 en cours, avec une actualisation des données cliniques prévue pour 2025 L’évaluation du pétosemtamab [...]

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

08/12/2024 - 18:40

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy of an Oral, [...]

TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

08/12/2024 - 18:35

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy 1 , 2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE [...]

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

08/12/2024 - 18:30

In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across [...]

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

08/12/2024 - 18:30

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse large B-cell [...]

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

08/12/2024 - 18:30

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key secondary endpoints [...]

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

08/12/2024 - 18:00

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of [...]

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

08/12/2024 - 18:00

The combination of acimtamig with AlloNK ® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments The [...]